Showing results (331-340 of 447) with videos related to

Sort By:
Pageof 45
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 StudyAkihito Kawazoe, Rui-Hua Xu, Pilar García-Alfonso, et al.
Cell Research|January 18, 2026
The AHCY-adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesisKun Liao, Fen Cao, Chen Wei, et al.
World Journal of Gastrointestinal Oncology|February 4, 2022
Characterization of E-cadherin expression in normal mucosa, dysplasia and adenocarcinoma of gastric cardia and its influence on prognosisHai-Ling Wang, Xue-Ke Zhao, Fu-You Zhou, et al.
Gut|September 7, 2021
Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatmentFeng Wang, You-Sheng Huang, Hao-Xiang Wu, et al.
American Journal of Cancer Research|October 12, 2020
Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm studyFeng Wang, Tian-Shu Liu, Xiang-Lin Yuan, et al.
Medcomm|August 12, 2025
Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal CancerYa-Shang Zheng, Wu-Hao Lin, Jun-Quan Chen, et al.
Gut|February 26, 2026
Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancerZhengyang Yang, Fan Xia, Jian Li, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|October 6, 2022
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNALiu-Fang Ye, Zi-Yao Huang, Xiao-Xi Chen, et al.
Med (New York, N.Y.)|June 13, 2024
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trialZi-Xian Wang, Junjie Peng, Xinjun Liang, et al.
Plos One|March 7, 2014
Patients with old age or proximal tumors benefit from metabolic syndrome in early stage gastric cancerXiao-li Wei, Miao-zhen Qiu, Huan-xin Lin, et al.
Pageof 45